Ordinary Index Rebalancing in the Solactive China Biotech Innovation Index | May 2021

In the ordinary rebalance the following composition will be implemented effective open 17.05.2021:

3SBIO INC
ALPHAMAB ONCOLOGY
ANHUI ANKE BIOTECHNOLOGY G-A
ASCENTAGE PHARMA GROUP INTERNATIONAL
BEIGENE LTD-ADR
BEIJING SL PHARMACEUTICAL -A
BEIJING TIANTAN BIOLOGICAL-A
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO LTD
BERRY GENOMICS CO LTD-A
BGI GENOMICS CO LTD-A
CHANGCHUN HIGH & NEW TECH-A
DA AN GENE CO LTD SUN YAT-A
FUJIAN ANJOY FOODS CO LTD
FUJIAN AONONG BIOLOGICAL T-A
GENSCRIPT BIOTECH CORP
GETEIN BIOTECH INC-A
GUANGDONG HYBRIBIO BIOTECH-A
GUANHAO BIOTECH CO LTD-A
HUALAN BIOLOGICAL ENGINEER-A
JINYU BIO-TECHNOLOGY CO LT-A
JOINN LABORATORIES CHINA CO LTD
JW CAYMAN THERAPEUTICS CO LT
KINTOR PHARMACEUTICAL LTD
PHARMABLOCK SCIENCES NANJI-A
SHANGHAI HAOHAI BIOLOGICAL-A
SHANGHAI RAAS BLOOD PRODUC-A
SHENZHEN KANGTAI BIOLOGICA-A
SHENZHEN NEPTUNUS BIOENG-A
SHENZHEN WEIGUANG BIOLOGIC-A
SICHUAN KELUN PHARMACEUTIC-A
SINO BIOPHARMACEUTICAL LTD ORD
VIVA BIOTECH HOLDINGS
WALVAX BIOTECHNOLOGY CO-A
WUXI BIOLOGICS CAYMAN INC
ZAI LAB LTD
ZHEJIANG WOLWO BIO-PHARMAC-A